Intellectual property has become the gold dust of modern commerce. Its possession and protection, the competition for it, and litigation over it dominate a growing range of industries – from pharmaceuticals and biotechnology to the many sectors involved in the Internet of Things.
Successfully defended Eli Lilly against patent infringement allegations by Sanofi involving medical device and formulation patents relating to Sanofi’s largest selling insulin.
Secured a successful verdict for Fairchild Semiconductor Corp. in a jury trial involving cross allegations of patent infringement against competitor Power Integrations, Inc.
Secured a complete defense victory for Trend Micro, Inc. against Intellectual Ventures in the District of Delaware on patent eligibility grounds, in a case purportedly worth US$150M.
Named Hatch-Waxman Litigation Team of the Year (Branded)LMG Life Sciences
Helping Clients Protect and Maximize Their IP
As IP increasingly takes center stage across industries, we are here to help our clients protect and leverage their IP in pursuit of new paths to growth. Our team is recognized for providing innovative solutions for our clients’ toughest challenges, with an emphasis on defending their interests in patent litigation and other IP disputes, as well as handling complex transactions in which IP plays a key role. We have experience in over 200 proceedings before the U.S. Patent Trial and Appeal Board, helping clients navigate this emerging and critical form of patent proceeding.
We continue to add top talent to bolster our capabilities in key jurisdictions and meet our clients’ evolving needs. Our significant growth strengthens our ability to help leading companies successfully contest patent matters across the U.S. and abroad.
Named 2019 Post-Grant Firm of the YearIntellectual Asset Management
A Unique Intellectual Property Practice
We represent Fortune 100 companies and other market leaders, as well as innovative start-ups, spanning a wide range of industries, products, and technologies.
Our global practice brings together IP litigation lawyers in key jurisdictions across the U.S., as well as in Asia and Europe.
We partner with scientific advisors and technical staff as needed to form cost-effective project teams with the right combination of sophisticated knowhow.
As an elite firm, Paul Hastings can provide complementary knowledge in related areas that influence the business success of technology and other IP-dependent companies, from finance and venture capital to employment law and trade secret agreements.
Named MVPs in IP, Technology, Life Sciences and AppellateLaw360
Named Winning Litigators and IP and Litigation TrailblazersNational Law Journal
Recognition For Our IP Practice
Recognized as Life Sciences Practice Group of the Year by Law360.
Named Pharmaceutical Team of the Year by Intellectual Property Magazine.
Won four awards by LMG Life Sciences including General Patent Litigator of the Year (New York), Post Grant Proceedings Attorney of the Year, and Two Impact Hatch-Waxman Cases of the Year.
Named Most Valuable Players – Life Sciences and IP by Law360.
Selected as Highly Recommended for General Litigation and Hatch Waxman Litigation (Branded) by LMG Life Sciences.
Recognized as a Winning Litigator by National Law Journal.
Named Transatlantic Lawyer of the Year – IP by The American Lawyer.
Recognized as Trailblazers in Litigation by National Law Journal.
Recognized as Top Tier for Intellectual Property Litigation by Benchmark Litigation.
Recognized as IP Star by Managing Intellectual Property and ranked in the Bio/Life Sciences, Copyright, and Patent Contentious categories.
Selected as a top firm in the Go-To IP Litigation Firm and Best for Complex IP Litigation categories in BTI Consulting Group’s Intellectual Property Outlook report.
Recognized as a top firm for Patent Litigation and Trade Secrets by the Legal 500 U.S.
Ranked among the Top 10 Litigation Practices in The American Lawyer’s Litigation Power Rankings.
Recognized as “one of the best pharmaceutical patent litigation outfits in the world” in the IAM Patent Litigation 1000.